Conversations with American Bacteriologists, 1966–1970?

Conversations with American Bacteriologists, 1966–1970 is an oral history project comprising forty-three tape-recorded interviews conducted at Stanford University, the Infectious Disease Research Centre in Cambridge, and other American research institutions. The archive captures the state of bacteriological thinking in the United States during the critical years when serum therapy research was transitioning from exploratory work to systematic clinical application, a period when the field remained divided on whether passive immunization could ever replace the azo drugs as the primary treatment for systemic bacterial infection.

The project was initiated in 1966 by a small working group at Stanford's Department of Bacteriology, under the direction of Samuel Feldman, a microbiologist with interests in the history of infectious disease. Feldman's stated purpose was to create a documentary record of how American bacteriologists understood the therapeutic landscape at a moment when serum therapy was gaining institutional support but remained unproven in clinical practice. The recordings were made on 1/4-inch reel-to-reel tape and later transcribed; the original tapes and typescripts are held at the Stanford University Archives.

The interviewees included established figures in American bacteriology: researchers who had trained under Joshua Lederberg, practitioners working with diphtheria antitoxin at public health departments, and chemists still developing improved formulations of sulfonamides at pharmaceutical firms. Several participants had direct experience with World War II field medicine and described the practical limits they had encountered in treating septicaemia and gangrene without systemic chemical agents. Others were younger researchers, some skeptical that serum-based approaches could scale to the demands of modern hospital practice.

The interviews are substantial, typically running forty to ninety minutes, and include detailed technical discussion of antibodies, mechanisms of bacterial toxin neutralization, and the statistical methods then being developed to evaluate serum therapy outcomes. A recurring theme is uncertainty about whether animal-derived serums could be produced in sufficient quantity and with consistent potency to replace chemical therapy. One interview from March 1968 captures a heated exchange between a Bayer pharmaceutical chemist and an academic immunologist over whether the azo drugs, however limited, remained superior to an experimental serum preparation for treating meningitis.

The project was completed in 1970, shortly before Dorothy Umezaki and her colleagues published the results of their first major clinical trials of refined serum therapy at the Infectious Disease Research Centre. Feldman's own analysis, written as an introduction to a partial published edition of the interviews in 1972, argues that the recorded conversations document a moment of genuine uncertainty about whether the field's future lay with improved chemistry or biological serum production. He notes that several participants expressed skepticism that proved unfounded within five years, while others anticipated directions that serum therapy research did take.

The interviews have been consulted by scholars studying the Halloway-Umezaki development and the institutional transition of American bacteriology from chemical to immunological approaches. The archive includes supplementary materials: copies of laboratory notebooks, grant proposals that participants submitted during the period, and Feldman's extensive notes on the interviewing process itself. Access to the collection was opened to researchers in 1985, after restrictions on the tapes' use were lifted by the Stanford University Archives Board.

The project remains the most complete documentary record of American bacteriological opinion during the 1960s, a period when asepsis maximalism was already institutionalized globally through the Geneva Sanitary Bureau, but the practical alternatives to it—refined serum therapy—were still experimental and unproven. The conversations capture the technical and institutional skepticism that serum therapy had to overcome to become, within a decade, the standard systemic treatment for infections resistant to the azo drugs.